Beam Therapeutics sued YolTech Therapeutics and Serapha Bio, alleging theft of Beam’s CRISPR base editing trade secrets and confidential information used to build a rival therapy platform. Beam claims a former scientist accessed internal data and then helped spin up YolTech’s activities, while Serapha Bio is accused of licensing the resulting therapy. The lawsuit reflects intensifying scrutiny around intellectual property boundaries in gene editing, especially as cross-border development and partnerships increase. Beam framed its claims as copying of its technology and an improper route to a competing rare disease treatment. Defendants reportedly deny the allegations, setting up a legal dispute that may influence how gene-editing IP is negotiated and audited across teams and geographies. For the sector, the case underscores how next-generation editing platforms may carry heightened IP risk in parallel with rising commercial interest.